evrysdi
roche registration gmbh - risdiplam - muskelatrofi, spinal - andre midler mod forstyrrelser i muskel-skeletsystemet - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikulært - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
lexotan 6 mg tabletter
roche a/s - bromazepam - tabletter - 6 mg
copegus 200 mg filmovertrukne tabletter
roche a/s - ribavirin - filmovertrukne tabletter - 200 mg
copegus 400 mg filmovertrukne tabletter
roche a/s - ribavirin - filmovertrukne tabletter - 400 mg
madopar "125" 100+25 mg kapsler, hårde
roche pharmaceuticals a/s - benserazidhydrochlorid, levodopa - kapsler, hårde - 100+25 mg
madopar "250" 200+50 mg kapsler, hårde
roche a/s - benserazidhydrochlorid, levodopa - kapsler, hårde - 200+50 mg
madopar quick 125 100+25 mg dispergible tabletter
roche pharmaceuticals a/s - benserazidhydrochlorid, levodopa - dispergible tabletter - 100+25 mg
pulmozyme 1 mg/ml inhalationsvæske til nebulisator, opløsning
roche pharmaceuticals a/s - dornase alfa - inhalationsvæske til nebulisator, opløsning - 1 mg/ml